Alto Neuroscience (ANRO) financial statements
Net income was -$63M.
Free cash flow was -$52M.
The diluted share count rose 673% over the period (dilution).
Income statement
Fiscal years, from Alto Neuroscience's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Research and development | $30M | $47M | $46M |
| Selling, general and admin | $8M | $22M | $21M |
| Operating income | -$38M | -$69M | -$66M |
| Interest expense | $1M | $1M | $2M |
| Income tax | $0 | $0 | $0 |
| Net income | -$36M | -$61M | -$63M |
| EPS (diluted) | -$9.73 | -$2.50 | -$2.19 |
| Diluted shares | 4M | 25M | 29M |
Balance sheet
Fiscal years, from Alto Neuroscience's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Cash and short-term investments | $83M | $168M | $176M |
| Total current assets | $85M | $169M | $178M |
| Property, plant and equipment | $1M | $3M | $2M |
| Total assets | $87M | $178M | $185M |
| Total current liabilities | $6M | $10M | $11M |
| Long-term debt | $10M | $10M | $16M |
| Total liabilities | $17M | $26M | $34M |
| Shareholders' equity | -$72M | $151M | $151M |
| Net debt | -$73M | -$158M | -$160M |
Cash flow
Fiscal years, from Alto Neuroscience's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating cash flow | -$33M | -$47M | -$52M |
| Capital spending | $470,000 | $2M | $24,000 |
| Free cash flow | -$34M | -$49M | -$52M |
| Stock-based compensation | $3M | $8M | $8M |
| Net borrowing | — | $0 | -$10M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ANRO.
Open ANRO in InvestinglyQuestions
How much free cash flow does Alto Neuroscience generate?
-$52M in fiscal 2025 (operating cash flow minus capital spending).
From Alto Neuroscience's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.